Puffy hands and fingers, as well as other symptoms, can precede the “warning sign” of Raynaud’s syndrome as the initial ...

A new interdisciplinary model for systemic sclerosis integrates imaging, AI, and personalized care to detect cardiac ...

Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren's disease. Both trials met the primary endpoint of ...

Kris Aquino announced Monday she will enter a six-month preventive isolation period as part of her treatment for multiple ...

First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial ...

In June 2025, Cabaletta closed an underwritten public offering consisting of shares of its common stock, pre-funded warrants and accompanying common stock warrants. The net proceeds from the offering ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in ...

New therapies harness the body’s cancer-fighting powers, but they don't work for everyone. UChicago experts aim to change ...

No revenue reported as clinical programs remain in precommercial stages. Workforce and cost reductions are expected to extend cash runway into the fourth quarter of 2026. Adicet Bio (NASDAQ:ACET), a ...